AB0458 Better retention rate at 5 years of anti-TNF agents used in conjonction with methotrexate over time in patients with rheumatoid arthritis: Real-life data from rhumadata computarized database

2013 ◽  
Vol 71 (Suppl 3) ◽  
pp. 663.14-663 ◽  
Author(s):  
D. Choquette ◽  
J.-P. Raynauld ◽  
B. Haraoui ◽  
D. Sauvageau
2016 ◽  
Vol 68 (4) ◽  
pp. 432-439 ◽  
Author(s):  
Ennio Giulio Favalli ◽  
Francesca Pregnolato ◽  
Martina Biggioggero ◽  
Andrea Becciolini ◽  
Alessandra Emiliana Penatti ◽  
...  

RMD Open ◽  
2019 ◽  
Vol 5 (2) ◽  
pp. e000969
Author(s):  
Sytske Anne Bergstra ◽  
Maura C Couto ◽  
Nimmisha Govind ◽  
Arvind Chopra ◽  
Karen Salomon Escoto ◽  
...  

ObjectiveTo investigate associations between baseline presence of erosions and/or anti-citrullinated protein antibodies (ACPA) on functional ability, disease activity and treatment survival over time.MethodsReal life data from newly diagnosed rheumatoid arthritis patients were identified in the international METEOR registry. Patients were grouped according to presence/absence of ACPA and/or erosions at baseline. Associations between the presence of ACPA and/or erosions (four groups) with the change of Disease Activity Score (DAS) and Health Assessment Questionnaire (HAQ) over time were assessed using linear mixed models during maximum 6 or maximum 12 months from baseline. Treatment survival was assessed using multiple failure-times Cox regression.ResultsData were included from 701 ACPA‒/erosions‒, 334 ACPA‒/erosions+, 1585 ACPA+/erosions‒ and 1993 ACPA+/erosions+ patients. We found statistically significant differences in DAS and HAQ change over time between the four groups, both after maximum follow-up durations of 6 and of 12 months, but after stratification differences proved small and not clinically meaningful. Patients in the ACPA‒/erosions‒ group were less likely to switch treatment compared with the ACPA+/erosions‒ reference group (p<0.001). The other two ACPA/erosions groups did not differ from the reference group.ConclusionsIn this analysis of worldwide real life data, we found statistically significant, but clinically irrelevant differences in treatment response to initial disease modifying anti-rheumatic drug therapies as measured by DAS and HAQ in ACPA‒/erosions‒, ACPA‒/erosions+, ACPA+/erosions‒ and ACPA+/erosions+ rheumatoid arthritis patients. However, after maximum follow-up durations of 6 and 12 months all groups had a similar response to initial treatment, but with a lower likelihood to switch treatment for ACPA‒/erosions‒ patients during the first year of follow-up.


Author(s):  
R. Expósito-Molinero ◽  
R. Garcia-Portales ◽  
J.R. Lamua-Riazuelo ◽  
A. Urruticoechea-Arana ◽  
P. Navarro-Alonso ◽  
...  

2014 ◽  
Vol 2014 ◽  
pp. 1-8 ◽  
Author(s):  
Matteo Filippini ◽  
Chiara Bazzani ◽  
Fabiola Atzeni ◽  
Piercarlo Sarzi Puttini ◽  
Antonio Marchesoni ◽  
...  

This study involving 1033 patients with RA confirms the effectiveness of etanercept, adalimumab, and infliximab in reducing RA-related disability even in patients with a history of highly active and longstanding RA. Moreover, we found that the improvement in disability was biphasic, with a marked improvement during the first year of anti-TNF therapy, followed by slower but significant recovery over the subsequent four years.


2017 ◽  
Vol 36 (4) ◽  
pp. 753-761 ◽  
Author(s):  
Sara Monti ◽  
Catherine Klersy ◽  
Roberto Gorla ◽  
Piercarlo Sarzi-Puttini ◽  
Fabiola Atzeni ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document